Shares of Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive data from Cohort 1 of the ongoing Phase 1b clinical trial evaluating the safety and tolerability of inhaled LTI-03 in patients diagnosed with idiopathic pulmonary fibrosis (IPF). LTI-03 is a novel, Caveolin-1-related peptide that addresses both inhibition of pro-fibrotic signaling and survival of critical epithelial cells.Following inhaled administration of low dose LTI-03, a positive trend was observed in seven out of eight biomarkers with evidence of reduced expression among profibrotic proteins produced by basal-like cells and fibroblasts that contribute to the progression of IPF, including data from several biomarkers that were statistically significant, reinforcing the potential of LTI-03 to improve lung function and reverse the course of IPF..

Aileron Therapeutics，Inc.（ALRN）的股票周三宣布了正在进行的1b期临床试验队列1的阳性数据，该试验评估了吸入LTI-03在诊断为特发性肺纤维化（IPF）的患者中的安全性和耐受性。LTI-03是一种新型的小窝蛋白-1相关肽，可抑制促纤维化信号传导和关键上皮细胞的存活。吸入低剂量LTI-03后，在八分之七的生物标志物中观察到阳性趋势，有证据表明基底样细胞和成纤维细胞产生的促纤维化蛋白表达降低，这有助于IPF的进展，包括来自几种生物标志物的数据具有统计学意义，增强了LTI-03改善肺功能和逆转IPF进程的潜力。。

'We find it encouraging that low dose LTI-03 achieved statistical significance in three out of eight biomarkers evaluated in the trial' said Brian Windsor, Ph.D., President and Chief Executive Officer of Aileron. 'This, paired with the positive trends observed in several of the other biomarkers, strengthens our belief that LTI-03 has the potential for disease stabilization or even reversal.

副翼总裁兼首席执行官布莱恩·温莎（BrianWindsor）博士说：“我们发现令人鼓舞的是，低剂量LTI-03在试验评估的八种生物标志物中有三种具有统计学意义。”这与其他几种生物标志物中观察到的积极趋势相结合，增强了我们的信念，即LTI-03具有疾病稳定甚至逆转的潜力。

We look forward to continuing to evaluate LTI-03 in the ongoing Phase 1b study and sharing results from the high-dose cohort later this year.' For comments and feedback contact: editorial@rttnews.comBusiness News.

我们期待着在正在进行的1b期研究中继续评估LTI-03，并在今年晚些时候分享高剂量队列的结果。”如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局决定生物技术股